VELSIPITY®

Hold Company

PFIZER

Learn More

Dosage and Administration

TABLET;ORAL

Specification

EQ 2MG BASE

Indication

Velsipity® is indicated for the treatment of moderately to severely active ulcerative colitis (UC) in adults.

Use

Instructions for Use

API

ETRASIMOD ARGININE

API Structure

We Supply

ETRASIMOD

Drug Patent

Patent No	Expiration Date
10301262	2036/6/21
10676435	2036/6/21
11007175	2036/1/6
11091435	2036/6/21
11884626	2036/6/21
12156866	2036/1/6
8580841	2030/3/5
9126932	2029/7/22

API Patent

Patent No	Expiration Date
10301262	2036/6/21
10676435	2036/6/21
11091435	2036/6/21
11884626	2036/6/21
8580841	2030/3/5
9126932	2029/7/22

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.